logo
Plus   Neg
Share
Email

Sanofi - Principia Biopharma Deal Receives U.S. Antitrust Approval

Sanofi (SNYNF,SNY) said that the Hart-Scott-Rodino waiting period has expired for Sanofi's acquisition of Principia Biopharma Inc. (PRNB).

On August 28, 2020, Sanofi commenced a tender offer to purchase all outstanding shares of common stock of Principia for $100 per share in cash. The offer is scheduled to expire on September 25, 2020, unless the offer is extended.

The consummation of the offer remains subject to various conditions, including the tender of at least a majority of the shares outstanding immediately prior to the expiration of the offer and other customary conditions.

Sanofi said in Mid-August that it agreed to acquire Principia Biopharma, a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, for $100 per share in cash, representing an aggregate equity value of about $3.68 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Co. filed a lawsuit against Siemens Energy AG, accusing the German power distribution company of stealing trade secrets for gas turbines. Siemens Energy allegedly used the information to get at least nine contracts to supply gas turbines to public utilities, and also covered up improper business gains. Following a court ruling, the U.S. Food and Drug Administration postponed the effective date for tobacco manufacturing companies to display new health warnings on cigarette packets and in advertisements, by additional 90 days. The warnings with color images is to promote greater public understanding of the negative health consequences of smoking. JPMorgan Chase & Co (JPM) reported strong results in the fourth quarter of 2020, with net profit up 42% largely driven by credit reserve releases of $2.9 billion. The Group said it ended the year with a CET1 ratio of 13.1% and capital above $200 billion, providing with meaningful capacity to further...
Follow RTT